These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 11532635)

  • 21. [Comparison of conditioning regimens containing or no fludarabine in nonmyeloablative allogeneic peripheral blood stem cell transplantation].
    Guo M; Yu CL; Wang DH; Qiao JH; Sun WJ; Shi BF; Zhang S; Sun QY; Yao B; Ai HS
    Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):413-5. PubMed ID: 14642178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Relevance of Apheretic Graft Composition in Patients With Acute Myeloblastic Leukemia Who Received a Busulfan-Fludarabine-Antithymocyte Globulin Conditioning Regimen for Allogeneic Transplant.
    Yeral M; Kasar M; Boga C; Kozanoglu I; Ozdogu H; Sariturk C
    Exp Clin Transplant; 2015 Oct; 13(5):453-60. PubMed ID: 26103468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
    Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
    Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.
    Shapira MY; Or R; Resnick IB; Bitan M; Ackerstein A; Samuel S; Elad S; Zilberman I; Miron S; Slavin S
    Bone Marrow Transplant; 2003 Sep; 32(6):557-61. PubMed ID: 12953126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
    Cesaro S; Gazzola MV; Marson P; Calore E; Caenazzo L; Destro R; De Silvestro G; Varotto S; Pillon M; Zanesco L; Messina C
    Am J Hematol; 2003 Feb; 72(2):143-6. PubMed ID: 12555220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
    Casper J; Wilhelm S; Steiner B; Wolff D; Grobe N; Hähling D; Hartung G; Hilgendorf I; Lück A; Junghanss C; Kahl C; Baumgart J; Pichlmeier U; Freund M
    Dtsch Med Wochenschr; 2005 Sep; 130(38):2125-9. PubMed ID: 16172951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
    Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility of the fludarabine busulfan 3 days and ATG 2 days reduced toxicity conditioning in 51 allogeneic hematopoietic stem cell transplantation: a single-center experience.
    Chantepie SP; Gac AC; Reman O
    Leuk Res; 2014 May; 38(5):569-74. PubMed ID: 24655805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation.
    Guilcher GM; Moorjani R; Truong TH; Lewis VA
    Bone Marrow Transplant; 2015 Mar; 50(3):455-6. PubMed ID: 25486583
    [No Abstract]   [Full Text] [Related]  

  • 31. Allogeneic non-myeloablative stem cell transplantation for the patients with heavily pre-treated refractory lymphoma.
    Lee JH; Lee JH; Kang YK; Lee JS; Kim WK; Lee KH
    Haematologica; 2001 Oct; 86(10):1114-5. PubMed ID: 11602425
    [No Abstract]   [Full Text] [Related]  

  • 32. Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan.
    Niiya H; Kanda Y; Saito T; Ohnishi T; Kanai S; Kawano Y; Kamijo K; Iizuka A; Yakushijin K; Ueda K; Chizuka A; Iijima K; Ohnishi M; Nakai K; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
    Haematologica; 2001 Oct; 86(10):1071-4. PubMed ID: 11602413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning.
    Johansson JE; Brune M; Ekman T
    Bone Marrow Transplant; 2001 Oct; 28(8):737-42. PubMed ID: 11781624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
    Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-TBI stem cell transplantation protocol for Fanconi anaemia using HLA-compatible sibling and unrelated donors.
    de la Fuente J; Reiss S; McCloy M; Vulliamy T; Roberts IA; Rahemtulla A; Dokal I
    Bone Marrow Transplant; 2003 Oct; 32(7):653-6. PubMed ID: 13130311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation.
    Jabbour E; Rondon G; Anderlini P; Giralt SA; Couriel DR; Champlin RE; Khouri IF
    Bone Marrow Transplant; 2007 Sep; 40(5):431-5. PubMed ID: 17603511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Seventeen cases of nonmyeloablative stem cell transplantation using a conditioning regimen containing fludarabine].
    Wu DP; Ma X; Sun AN; Fu ZZ; Tang XW; Qiu HY; Miao M; Liu YJ; Li CX; Xia XM; Lin BJ
    Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):410-2. PubMed ID: 14642177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.
    Alessandrino EP; Bernasconi P; Colombo AA; Caldera D; Malcovati L; Troletti D; Vanelli L; Varettoni M; Montanari F; Lazzarino M
    Bone Marrow Transplant; 2004 Dec; 34(12):1039-45. PubMed ID: 15516936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5 %-a feasibility study.
    Choi EJ; Lee JH; Lee JH; Kim DY; Park HS; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
    Ann Hematol; 2016 Jun; 95(7):1151-61. PubMed ID: 27106699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.